Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study*
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Since immunomodulators and antitumor necrosis factor (TNF) agents are increasingly used to treat inflammatory bowel disease (IBD), it is recommended to administer antipneumococcal vaccination to prevent opportunistic pneumonia. There is some evidence that concomitant immunosuppression may impair the immune response to vaccination. We aimed to evaluate the response rates to pneumococcal vaccination in four different treatment groups (mesalamine, azathioprine, infliximab, infliximab plus azathioprine). METHODS: In all, 96 patients with IBD (54 with Crohn's disease; 42 with ulcerative colitis) were administered a 23-valent polysaccharide pneumococcal vaccine (PSV-23). The levels of antipneumococcal antibodies were measured prior to and at least 3 weeks after vaccination. Response rates and risk factors for impaired immunosuppression were investigated. Patients on mesalamine were used as a control group. RESULTS: Patients administered infliximab or the combination immunosuppressive therapy had significantly lower response rates to vaccination (57.6% and 62.5%, respectively) compared with the group on mesalamine (88.6%; P < 0.05 for both comparisons). Azathioprine alone did not influence the response rate to vaccination (78.9%; P = 0.43 vs. mesalamine group). Mean antibody titers after vaccination were significantly lower in patients under infliximab or combined immunosuppression than controls (P < 0.05). Immunosuppression with infliximab or combination therapy significantly decreased the likelihood of responding to vaccination (odds ratio [OR] = 0.17, 95% confidence interval [CI] 0.04-0.64, P = 0.009, and OR = 0.21, 95% CI 0.05-0.91, P = 0.038, respectively). Pneumococcal vaccination was generally safe and well tolerated. CONCLUSIONS: Anti-TNF therapy alone or in combination with azathioprine impairs the response to pneumococcal vaccination in patients with IBD. All patients with IBD should therefore be vaccinated before starting anti-TNF therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Satsangi, J., Silverberg, M. S., Vermeire, S., & Colombel, J.-F. (2006) · Gut · doi:10.1136/gut.2005.082909 · Cited by 3,176 · cited 4×
“The level of clinical disease activity was assessed using the Harvey–Bradshaw index (HBI) for CD19 and the Mayo Clinic subscore for UC.20 No endoscopic assessment of disease activity was requested for the study.”
MethodInfluentialInfliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143 · cited 2×
“As an alternative to steroids, the combination of azathioprine and infliximab seems to be more effective than immunosuppressive monotherapy in increasing the chances of therapeutic response in patients with active CD.(4) Prolonged and continued pharmacological immunosuppression in patients with IBD can cause some adve…”
BackgroundA SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY
Harvey, R. F., & Bradshaw, J. M. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92767-1 · Cited by 2,959
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498 · cited 1×
“Recent European guidelines recommend the use of steroids as the first-choice approach to treating CD, as well as suggesting early introduction of immunomodulators or biological agents such as antitumor necrosis factor (TNF) to minimize prolonged steroid use and in the case of relapse.(3) As an alternative to steroids,…”
BackgroundSelf-citationRisk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease
Toruner, M., Loftus, E. V., Harmsen, W. S., Zinsmeister, A. R., Orenstein, R., Sandborn, W. J., Colombel, J., & Egan, L. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.012 · Cited by 1,017 · cited 1×
“Prolonged and continued pharmacological immunosuppression in patients with IBD can cause some adverse events, particularly the increased risk of opportunistic infections, which can even be fatal.(5) Bacterial, viral, and fungal infections can be potentially dangerous during the course of immunosuppression, and accurat…”
BackgroundRahier, J. F., Ben-Horin, S., Chowers, Y., Conlon, C., De Munter, P., D'Haens, G., Domènech, E., Eliakim, R., Eser, A., Frater, J., et al. (2009) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.02.010 · Cited by 738 · cited 2×
“strongly recommend vaccination against potentially severe infectious agents, such as influenza, pneumococcus, and the hepatitis B virus (HBV).(6,7) Streptococcus pneumoniae is the most common cause of community-acquired pneumonia, and causes up to 500,000 cases of pneumonia a year in the United States.”
BackgroundMethodInfections in patients with rheumatoid arthritis treated with biologic agents
Listing, J., Strangfeld, A., Kary, S., Rau, R., von Hinueber, U., Stoyanova‐Scholz, M., Gromnica‐Ihle, E., Antoni, C., Herzer, P., Kekow, J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21386 · Cited by 681 · cited 1×
“However, immunocompromised patients are at an increased risk of developing pneumococcal pneumonia, which can cause up to 25% of deadly infections in patients with chronic immune-mediated diseases requiring prolonged immunosuppression.(10,11) Importantly, there is an increased risk of pneumococcal pneumonia in patients…”
BackgroundSutherland, L. R., Martin, F., Greer, S., Robinson, M., Greenberger, N., Saibil, F., Martin, T., Sparr, J., Prokipchuk, E., & Borgen, L. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90621-4 · Cited by 677 · cited 4×
“The level of clinical disease activity was assessed using the Harvey–Bradshaw index (HBI) for CD19 and the Mayo Clinic subscore for UC.20 No endoscopic assessment of disease activity was requested for the study.”
MethodInfluentialAskling, J., Fored, C. M., Brandt, L., Baecklund, E., Bertilsson, L., Feltelius, N., Cöster, L., Geborek, P., Jacobsson, L. T., Lindblad, S., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062760 · Cited by 334 · cited 1×
“Importantly, there is an increased risk of pneumococcal pneumonia in patients with IBD and prevention by vaccination is thus strongly recommended.(12) Vaccination should be done as early as possible, as the risk of opportunistic infections increases following the first year of pharmacological immunosuppression.”
BackgroundEtiopathogenesis of inflammatory bowel diseases
Danese, S., & Fiocchi, C. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.12.4807 · Cited by 327
Self-citationPatients with Inflammatory Bowel Disease Are at Risk for Vaccine-Preventable Illnesses
Melmed, G. Y., Ippoliti, A. F., Papadakis, K. A., Tran, T. T., Birt, J. L., Lee, S. K., Frenck, R. W., Targan, S. R., & Vasiliauskas, E. A. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00646.x · Cited by 326 · cited 1×
“Vaccination should be done as early as possible, as the risk of opportunistic infections increases following the first year of pharmacological immunosuppression.(13) Despite this advice, one study has shown that only 9% of patients with IBD have received a pneumococcal vaccination.”
BackgroundKapetanovic, M. C., Saxne, T., Sjöholm, A., Truedsson, L., Jönsson, G., & Geborek, P. (2006) · Rheumatology · doi:10.1093/rheumatology/kei193 · Cited by 319 · cited 1×
“Our findings also align with the results from a study on pneumococcal vaccination in patients with RA who were treated with anti-TNF and methotrexate, even though methotrexate seemed to be the main cause of the impaired response to vaccination in that study.(25) Unfortunately, other studies on pneumococcal vaccination…”
ResultIntestinal inflammation: a complex interplay of immune and nonimmune cell interactions
Fiocchi, C. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g769 · Cited by 216 · cited 1×
“Both of them share certain pathogenic features due to the underlying proinflammatory cytokines and immune system mechanisms that are actively involved in triggering and maintaining chronic inflammation in the gut.(1,2) Recent European guidelines recommend the use of steroids as the first-choice approach to treating CD…”
BackgroundImmunopathogenesis and spectrum of infections in systemiclupus erythematosus
ILIOPOULOS, A., & TSOKOS, G. (1996) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(96)80018-7 · Cited by 206 · cited 1×
“However, immunocompromised patients are at an increased risk of developing pneumococcal pneumonia, which can cause up to 25% of deadly infections in patients with chronic immune-mediated diseases requiring prolonged immunosuppression.(10,11) Importantly, there is an increased risk of pneumococcal pneumonia in patients…”
BackgroundVaccinations in patients with immune-mediated inflammatory diseases
Rahier, J.-F., Moutschen, M., Van Gompel, A., Van Ranst, M., Louis, E., Segaert, S., Masson, P., & De Keyser, F. (2010) · Rheumatology · doi:10.1093/rheumatology/keq183 · Cited by 200 · cited 2×
“Differently, another study concerning patients with rheumatoid arthritis (RA) found no differences in the response to vaccination in patients treated with adalimumab or placebo.(18) In contrast to the effect of treatment with an anti-TNF biological therapy observed here, treatment with the thiopurine azathioprine alon…”
ResultMelmed, G. Y., Agarwal, N., Frenck, R. W., Ippoliti, A. F., Ibanez, P., Papadakis, K. A., Simpson, P., Barolet-Garcia, C., Ward, J., Targan, S. R., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.523 · Cited by 181 · cited 6×
“Considering the available data in the literature, expected response rates for IBD patients not on immunosuppressive therapy, and IBD subjects receiving immunosuppressive therapy (those divided in three equal subpopulation based on their specific treatment) were 80% and 40%, respectively.(17) To achieve 80% power with…”
BackgroundResultInfluentialA Practical Guide to Vaccinating the Inflammatory Bowel Disease Patient
Wasan, S. K., Baker, S. E., Skolnik, P. R., & Farraye, F. A. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.733 · Cited by 179 · cited 1×
“strongly recommend vaccination against potentially severe infectious agents, such as influenza, pneumococcus, and the hepatitis B virus (HBV).(6,7) Streptococcus pneumoniae is the most common cause of community-acquired pneumonia, and causes up to 500,000 cases of pneumonia a year in the United States.”
BackgroundImmune Response to Influenza Vaccine in Pediatric Patients With Inflammatory Bowel Disease
Mamula, P., Markowitz, J. E., Piccoli, D. A., Klimov, A., Cohen, L., & Baldassano, R. N. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.02.035 · Cited by 175
Visvanathan, S., Keenan, G. F., Baker, D. G., Levinson, A. I., & Wagner, C. L. (2007) · PubMed · Cited by 130
MEASURING CROHN'S DISEASE ACTIVITY
Harvey, R., & Bradshaw, M. J. (1980) · The Lancet · doi:10.1016/s0140-6736(80)91577-9 · Cited by 129
Pneumococcal vaccines: history, current status, and future directions
Butler, J. C., Shapiro, E. D., & Carlone, G. M. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00105-9 · Cited by 110 · cited 1×
“Despite this advice, one study has shown that only 9% of patients with IBD have received a pneumococcal vaccination.(14) Up to 98% of the pneumococcal serotypes that cause pneumonia in the industrialized world are contained in the PSV-23 vaccine, which results in a high rate of protection against pneumonia in vaccinat…”
Brezinschek, H. P., Hofstaetter, T., Leeb, B. F., Haindl, P. M., & Graninger, W. B. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3282ffdeca · Cited by 45 · cited 1×
“Unfortunately, other studies on pneumococcal vaccination in patients with RA treated with infliximab and/or methotrexate did not confirm these results.(26,27) Although our patient population was larger, we did not evaluate the role of methotrexate on response to vaccination in this study and further studies on whether…”
ResultStimulation of dna synthesis by ascorbate in cultures of articular chondrocytes
Krystal, G. W., Morris, G. M., & Sokoloff, L. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780250309 · Cited by 34
Pneumococcal vaccination in adults: recommendations, trends, and prospects.
Targonski, P. V., & Poland, G. A. (2007) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.74.6.401 · Cited by 23 · cited 1×
“Up to 98% of the pneumococcal serotypes that cause pneumonia in the industrialized world are contained in the PSV-23 vaccine, which results in a high rate of protection against pneumonia in vaccinated patients.(15) Even though it does not result in a T-cell-mediated or memory response, the vaccine induces production o…”
Background
Cited by
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Kucharzik, T., Ellul, P., Greuter, T., Rahier, J. F., Verstockt, B., Abreu, C., Albuquerque, A., Allocca, M., Esteve, M., Farraye, F. A., et al. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab052 · Cited by 480
ACG clinical guideline: Preventive care in inflammatory bowel disease
Farraye, F. A., Melmed, G. Y., Lichtenstein, G. R., & Kane, S. V. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.537 · Cited by 473
Clinical use of anti-TNF therapy and increased risk of infections
Ali, T., Bronze, Kaitha, Mahmood, Ftaisi, & Stone (2013) · Drug, Healthcare and Patient Safety · doi:10.2147/dhps.s28801 · Cited by 242
“Anti-TNF therapy may impair the response to pneumococcal vaccination, so the vaccine is usually recommended $ 2–3 weeks prior to starting antiTNF therapy.(41)”
Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease
Marín, A. C. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i40.11273 · Cited by 58
Metadata
- Authors
- Fiorino, G., Peyrin-Biroulet, L., Naccarato, P., Szabò, H., Sociale, O. R., Vetrano, S., Fries, W., Montanelli, A., Repici, A., Malesci, A., & Danese, S.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-06
- Volume
- 18
- Issue
- 6
- Pages
- 1042-1047
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W2131198668
- Cited by
- 177
- References
- 24
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.